Board committees
The board of directors has set up two committees; the audit committee and the remuneration committee. The board of directors has adopted rules of procedure for each of these committees.
Audit committee
The audit committee’s role is primarily to monitor the Company’s financial position, to monitor the effectiveness of the Company’s internal control, internal audit and risk management, to be informed about the audit of the annual report and consolidated financial statements, and to review and monitor the auditor’s impartiality and independence. The audit committee shall also assist the nomination committee in proposals for resolutions on the election and remuneration of the auditor.
The audit committee is comprised of Christine Rankin (chairman), Per Wold-Olsen and Per Samuelsson.
Remuneration committee
The remuneration committee’s role is primarily to prepare matters regarding remuneration and other terms of employment for the CEO and other members of senior management. The remuneration committee shall also monitor and evaluate ongoing and completed programmes for variable remuneration to the Company’s management and monitor and evaluate the implementation of the guidelines for remuneration to senior management adopted by the annual general meeting.
The remuneration committee is comprised of Per Wold-Olsen (chairman), Brian Stuglik and Per Samuelsson.
Nomination committee 2026
According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2026 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2025 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.
The Nomination Committee in respect of the annual general meeting 2026 consists of the following persons who together represent approximately 20 percent of the number of shares and votes in the company based on the shareholder information at end of September 2025.
- Staffan Lindstrand, appointed by HealthCap VI L.P.
- Jonas Brambeck, appointed by Jakob Lindberg
- Anna Henricsson appointed by Handelsbanken Funds
- Per Wold-Olsen, the Chairman of the Board
The Nomination Committee’s proposals will be presented in the Notice to the annual general meeting 2026 and and under Annual General Meeting 2026 here on the website.
Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to info@oncopeptides.com (subject “Nomination Committee”) or by letter posted to:
Oncopeptides AB (publ)
Attn: Oncopeptides Nomination Committee
Luntmakargatan 46
SE-111 37 Stockholm, Sweden
A proposal must reach the nomination committee no later than April 1, 2026, to be included in the notice to attend and the agenda for the annual general meeting.
About the Nomination committee
According to the Code, the Company shall have a nomination committee which duties shall include the preparation and drafting of proposals regarding the election of members of the board of directors, the chairman of the board of directors, the chairman of the general meeting and auditors. The nomination committee shall also propose fees for the board members and the auditors.
At the annual general meeting held on May 17, 2018, it was resolved to adopt principles for the nomination committee to be valid until further notice. The nomination committee shall comprise of four members, representing the three largest shareholders at the end of the third quarter of each financial year, together with the chairman of the board of directors. The largest shareholders refers to the registered shareholders or otherwise known shareholders after the end of the third quarter. Before accepting an invitation to join the nomination committee, a member must carefully consider whether there is a conflict of interest.
The composition of the nomination committee shall be publicly announced on the Company’s website no later than six months prior to the annual general meeting. Should a representative resign or leave before the assignment is completed, the shareholder that appointed the departing member shall appoint a new member. Should a shareholder that has appointed a member of the nominating committee substantially decrease its ownership in the Company, the next shareholder in size order shall, if the nominating committee so resolves, be offered to appoint a member of the nominating committee. When such a representative has been appointed, he or she shall be a member to the nomination committee and replace the former committee member who no longer represents one of the three largest shareholders. The nomination committee shall fulfil the composition requirements set out in the Code.
If the major shareholders who have the right to appoint members to the nomination committee wish to appoint persons that would entail that the composition requirements, as set out in the Code, are not met, a larger shareholder shall have priority for their first choice of member over of a smaller shareholder. When appointing a new member as a result of significant changes in ownership, the shareholder who shall appoint a new member shall, when appointing a new member, consider the existing composition of the nomination committee.
The nominating committee shall appoint a chairman among its members. The chairman of the board of directors or other board member shall not be the chairman of the nomination committee. The mandate period of the appointed nomination applies until the appointment of a new nomination committee. Fees may be paid to the members of the nomination committee after a resolution by the general meeting.